Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- Check5 days agoChange DetectedStandardizes regional naming to 'Tatarstan, Respublika' and updates the Kazan address accordingly (v3.0.2); removes the 'Back to Top' link as a minor UI cleanup.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check20 days agoChange DetectedThe webpage has been updated with new facility names and locations, including specific cities and countries, as well as a new publication related to telisotuzumab vedotin. Additionally, the page now includes a new date for an estimated last update.SummaryDifference27%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check41 days agoChange DetectedThe webpage has added numerous new locations for hospitals and medical centers across various countries, including Greater London, Cluj, and several regions in Japan and Italy. Additionally, some previously listed locations have been removed, indicating a significant update to the availability of healthcare facilities.SummaryDifference26%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.